PT  - JOURNAL ARTICLE
AU  - Nagy-Szakal, Dorottya
AU  - Couto-Rodriguez, Mara
AU  - Wells, Heather L.
AU  - Barrows, Joseph
AU  - Debieu, Marilyne
AU  - Butcher, Kristin
AU  - Chen, Siyuan
AU  - Berki, Agnes
AU  - Hager, Courteny
AU  - Boorstein, Robert J.
AU  - Taylor, Mariah K.
AU  - Jonsson, Colleen B.
AU  - Mason, Christopher E.
AU  - O’Hara, Niamh B.
TI  - Targeted Hybridization Capture of SARS-CoV-2 and Metagenomics Enables Genetic Variant Discovery and Nasal Microbiome Insights
AID  - 10.1101/2021.03.16.21252988
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.16.21252988
4099  - http://medrxiv.org/content/early/2021/03/20/2021.03.16.21252988.short
4100  - http://medrxiv.org/content/early/2021/03/20/2021.03.16.21252988.full
AB  - The emergence of novel SARS-CoV-2 genetic variants that may alter viral fitness highlights the urgency of widespread next-generation sequencing (NGS) surveillance. To profile genetic variants, we developed and clinically validated a hybridization capture SARS-CoV-2 NGS assay, integrating novel methods for panel design using dsDNA biotin-labeled probes, and built accompanying software. The positive and negative percent agreement were defined in comparison to an orthogonal RT-PCR assay (PPA and NPA: both 96.7%). The limit of detection was established to be 800 copies/ml with an average fold-enrichment of 46,791x. We identified novel 107 mutations, including 24 in the functionally-important spike protein. Further, we profiled the full nasopharyngeal microbiome using metagenomics and found overrepresentation of 7 taxa and macrolide resistance in SARS-CoV-2-positive patients. This hybrid capture NGS assay, coupled with optimized software, is a powerful approach to detect and comprehensively map SARS-CoV-2 genetic variants for tracking viral evolution and guiding vaccine updates.TEASER This is the first target hybridization capture-based NGS assay to detect SARS-CoV-2 genetic variants for tracking viral evolution.Competing Interest StatementThe authors declare that DNS, MCR, JB, HLW, MD, AB, CH, CEM and NBO are employees of Biotia, Inc. KB and SC are employees of Twist Bioscience.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:De-identified samples were collected and processed under the IRB numbered Pro00042824 (Advarra).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate conclusions are present in the manuscript. Supplemental data and sequencing data were submitted to GISAID. https://www.gisaid.org/